OncoMatch/Clinical Trials/NCT06768905
Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma
Is NCT06768905 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Iomab-B and CAR-T cell for non hodgkin lymphoma.
Treatment: Iomab-B · CAR-T cell — This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion in patients with Relapsed or refractory (R/R) Diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoimmunotherapy
relapsed or refractory DLBCL or high-grade B-cell lymphoma (HGBL) following at least one or more prior chemoimmunotherapy regimen (with at least one course including an anthracycline and CD20-directed therapy)
Cannot have received: radiopharmaceutical
Patients with prior history of treatment with radiopharmaceuticals for any indication.
Cannot have received: external beam radiation therapy
Exception: except for treatment of cutaneous lesions and localized prostate cancer
Patients with a history of external beam radiation therapy except for treatment of cutaneous lesions and localized prostate cancer.
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0k/µL, Platelets ≥50k/µL, Hemoglobin ≥8g/dL, without requiring blood product or granulocyte-colony stimulating factor support in the 7 days prior to screening and start of 131I-Apamistamab treatment.
Kidney function
Creatinine clearance ≥50 mL/min as calculated by the Cockroft-Gault formula.
Liver function
Total bilirubin ≤1.5x upper limit of normal, AST and ALT ≤3x upper limit of normal (ULN), unless liver dysfunction is thought to be related to underlying malignancy or secondary to Gilbert's disease in which case the direct bilirubin should be ≤3.0 mg/dL, and AST and ALT ≤5x ULN.
Cardiac function
LVEF ≥40% as assessed by echocardiogram or MUGA scan. Exclude NYHA stage III or IV congestive heart failure, myocardial infarction ≤6 months prior to enrollment, any history of clinically significant ventricular arrhythmia or unexplained syncope.
Creatinine clearance ≥50 mL/min as calculated by the Cockroft-Gault formula. Total bilirubin ≤1.5x upper limit of normal , AST and ALT ≤3x upper limit of normal (ULN), unless liver dysfunction is thought to be related to underlying malignancy or secondary to Gilbert's disease in which case the direct bilirubin should be ≤3.0 mg/dL, and AST and ALT ≤5x ULN. Adequate bone marrow function: Absolute neutrophil count ≥1.0k/µL, Platelets ≥50k/µL, Hemoglobin ≥8g/dL. Impaired cardiac function (LVEF <40%) as assessed by echocardiogram or MUGA scan [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify